

February 22 2024

Immune cell receptor provides promising immunotherapy target



Activins promote the development of induced Tregs (iTregs) *in vitro* and *in vivo*. (a-b) naive CD4+ T cells were isolated from WT C57BL/6J mice, and then cultured *in vitro* with plate-bound anti-CD3, soluble anti-CD28, recombinant IL-2 and the indicated gradient concentrations of TGF-b for 3 days. The percentage of CD25^{high}Foxp3+ (a) and Foxp3+Ki67+ (b) in CD4+ cells were analyzed by flow cytometry. (c-d) WT C57BL/6J mice were inoculated with B16F10 tumors and treated with 50ng per mouse recombinant activin A or PBS every other day for 21 days. TILs and specified organs (draining lymph nodes shown as DLN, spleens shown as SP) were harvested from these mice and analyzed for the frequency of CD25^{high}Foxp3+ (c) and Foxp3+Ki67+ (d) in CD4+ cells by flow cytometry. (e) naive CD4+ T cells were isolated from WT C57BL/6J mice, and then stimulated with plate-bound anti-CD3, soluble anti-CD28, recombinant IL-2 in the absence or presence of recombinant activin A.



36 hours later, RNA was analyzed for the expression of indicated genes using qRT-PCR. Credit: *OncoImmunology* (2024). DOI: 10.1080/2162402X.2023.2297503

Drugs that target a receptor on immune cells called activin receptor 1C may combat tumor-induced immune suppression and help patients' immune systems fight back against cancer, according to a study by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

The study, <u>published</u> in *Oncoimmunology*, identifies a new strategy cancer cells use to protect themselves from immune system attack, and suggests treatments that could counteract it.

It shows that tumor cells and some immune cells produce proteins called activins that cause immune cells called CD4⁺ T helper cells—which send signals to other <u>immune cells</u> to destroy infectious particles—to transform into another type of T cell (regulatory T-cells, or Tregs), which performs the opposite function, suppressing immune system activity.

However, blocking activin receptor 1C on CD4⁺ T cells helps prevent the accumulation of immune-suppressing Tregs in tumors and slows tumor growth.

"We have identified a new target for anticancer immunotherapy," says the study's senior investigator, Drew Pardoll, M.D., P.h.D., director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy and professor of oncology at the Johns Hopkins University School of Medicine. "Our discovery could lead to an entirely new class of immunotherapies that may enhance the effects of existing cancer



therapies and further personalize cancer care."

Tregs are essential in preventing the immune system from attacking the body's cells and causing autoimmune diseases. But tumors co-opt this normally protective cell to defend themselves against destruction by the immune system, suppressing the body's built-in defenses to cancer. Patients with more Tregs have worse cancer outcomes, but studies in mice have shown that blocking Tregs inhibits tumor growth, and reducing Treg numbers causes tumors to shrink.

About a decade of research by Johns Hopkins researchers on the role of a transcription factor called YAP in Treg production in <u>tumor cells</u> led to the discovery that YAP boosts activin receptor 1C numbers on Tregs. The fact that this receptor only occurs on cells produced in the <u>bone</u> <u>marrow</u>, such as immune or blood cells, reduces the likelihood of harmful off-target effects.

In the study, the investigators demonstrated that mice genetically engineered to lack the activin receptor 1C are healthy, able to reproduce, and naturally resistant to <u>tumor growth</u>. Treating mice with an antibody that blocks the receptor also had anticancer effects. When combined with antibodies to a second inhibitory immune receptor, PD-1, which is used clinically to treat many cancers, the antibody had an even greater impact on tumors, even those that do not usually respond to anti-PD-1 therapies.

Because the human activin receptor 1C is almost identical to the mouse activin receptor 1C, Pardoll is hopeful that similar efficacy will be achieved in humans. The similarity will also help expedite preclinical studies testing anti-activin receptor 1C antibody therapy candidates. Pardoll and colleagues are partnering with Immunomic Therapeutics to develop several potential candidate antibodies.



"We hope to have an antibody available for <u>clinical trials</u> in 2025," he says.

If clinical trials are successful, the anti-activin receptor 1C antibodies could be a potent addition to the arsenal of anticancer drugs. Combining them with PD-1 inhibitors could improve treatment effectiveness. Pardoll explains that blood tests can identify patients with high levels of activin who may be more likely to benefit from anti-activin receptor 1C antibody therapies, allowing more precise identification of patients likely to benefit from the therapy.

More information: Ying Zheng et al, Targeting the activin receptor 1C on CD4+ T cells for cancer immunotherapy, *OncoImmunology* (2024). DOI: 10.1080/2162402X.2023.2297503

Provided by Johns Hopkins University School of Medicine

Citation: Immune cell receptor provides promising immunotherapy target (2024, February 22) retrieved 25 June 2024 from <u>https://medicalxpress.com/news/2024-02-immune-cell-receptor-immunotherapy.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.